Dr. Philippe SLOS

Philippe Slos studied at the Institut Supérieur Industriel du Hainaut (Belgium). He got his Ph.D in 90 at the Université Louis-Pasteur of Strasbourg (France). He is working since 1984 at Transgene SA in Strasbourg (France). His main research interest was fi rst to work on molecular biology of lactic acid bacteria. He then developped in vitro/translation systems of the CFTR cDNA (cystic fibrosis transmembrane conductance regulator) followed by the prokaryotic production of active canine IFN-γ.

Between 1992 and 1995, he investigated mucosal vaccine strategies using recombinant fusion proteins between cholera toxin subunit B and relevant immunodominant peptide epitopes. From 1993 to 1995, he developed a life vaccine based on lactic acid bacteria to induce mucosal immunity. Since 1996, he is working in the field of cancer immuno-gene therapy, first by performing preclinical studies using adenovirus-based vectors to deliver in situ cDNA coding for cytokines (IL-2 and IFN-γ). Between 1998 and 2000, he focussed on Ad-IFN-γ. Since 2001, he directs a project on Ad- IFN-γ and Ad-IL-2 industrial process. He became in 2005 Head of the Preclinical Regulatory Department of Transgene SA.